Rapport Therapeutics (RAPP) grants CFO 148,000 stock options

Rhea-AI Filing Summary

Rapport Therapeutics reported that its Chief Financial Officer, Troy Ignelzi, received a new stock option award. On February 2, 2026, he was granted an option to buy 148,000 shares of common stock at an exercise price of $27.75 per share. The option vests in 48 equal monthly installments following January 1, 2026, as long as he continues in service on each vesting date, and is scheduled to expire on February 2, 2036. After this grant, he directly beneficially owns 148,000 derivative securities in the form of this option.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ignelzi Troy A.

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.75	02/02/2026		A		148,000		(1)	02/02/2036	Common Stock	148,000	$0	148,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Troy Ignelzi	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rapport Therapeutics (RAPP) report for its CFO?

Rapport Therapeutics reported a stock option grant to its CFO. On February 2, 2026, Chief Financial Officer Troy Ignelzi received an option to purchase 148,000 shares of common stock at an exercise price of $27.75 per share as part of his compensation.

How many Rapport Therapeutics shares are covered by the CFO’s new stock option?

The new stock option covers 148,000 shares of common stock. This derivative security gives CFO Troy Ignelzi the right to buy up to 148,000 shares at a fixed exercise price of $27.75 per share, subject to the vesting schedule and expiration date.

What is the exercise price and term of the Rapport Therapeutics CFO stock option?

The option has a $27.75 exercise price and expires February 2, 2036. It is a stock option right to buy common stock, granted on February 2, 2026, providing a long-term window during which the CFO can exercise vested portions of the grant.

How does the CFO’s Rapport Therapeutics stock option vest over time?

The stock option vests in 48 equal monthly installments. Vesting begins after January 1, 2026, with a portion becoming exercisable each month, conditioned on CFO Troy Ignelzi’s continued service with the company on each respective vesting date.

How many derivative securities does the Rapport Therapeutics CFO own after this Form 4?

After the reported transaction, the CFO beneficially owns 148,000 derivative securities. All of these are in the form of the newly granted stock option, held directly, representing rights to acquire common shares under the specified vesting and exercise terms.

Is the Rapport Therapeutics CFO’s stock option grant reported as directly owned?

Yes, the stock option grant is reported as directly owned. The Form 4 lists the ownership form for the 148,000 stock option derivative securities as “D” for direct, meaning the award is attributed personally to CFO Troy Ignelzi rather than to an affiliated entity.